{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'COVID-19 and Influenza', 'In the spring of 2020 COVID-19 emerged late in the course of the 2019-2020 seasonal influenza', 'epidemic, with co-infection being reported in some individuals 11 Of potential concern, was', 'the', 'possibility of a simultaneous surge in both COVID-19 cases and influenza cases during the', '2020-2021 season. However, influenza activity in the United States during the 2020-2021', 'season remained relatively low. If both COVID-19 and influenza infections peaked', 'simultaneously during subsequent seasons, there could be a significant future impact on', 'utilization of health care resources potentially overburdening the health care system.', 'COVID-19 Vaccines', 'The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) (marketed as Comirnaty) received FDA-', 'licensure on August 23rd, 2021. It is currently the only FDA approved vaccine to prevent COVID-', '19 for individuals 16 years old or older. Numerous other COVID-19 vaccines are currently in', 'different phases of preclinical and clinical development. Five vaccines have recently completed', 'or are currently undergoing late stage Phase 3 clinical testing in the United States including two', 'mRNA vaccines, two viral vectored vaccines, and an adjuvanted recombinant vaccine12 As of', 'December 2020, the Moderna mRNA vaccine (mRNA-1273) received US Food and Drug', 'Administration (FDA) Emergency Use Authorization (EUA) for persons 18 years of age and', 'older13. Prior to recent approval, the Pfizer-BioNTech COVID-19 vaccine received an initial EUA', 'in December 2020 for persons 16 years of age and older and expanded its EUA to include', 'individuals 12 - -15 years of age on May 10, 2021. Both Pfizer-BioNTech and Moderna vaccines', 'are based on the SARS-CoV-2 spike glycoprotein (S) antigen encoded by RNA and formulated', 'in lipid nanoparticles (LNPs). Among study participants without evidence of SARS-CoV-2', 'infection, the Pfizer/BioNTech vaccine (BNT162b2) was 95.0% (95% CI 90.3%, 97.6%) effective', 'at preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine 14', 'The Moderna vaccine (mRNA-1273) demonstrated a vaccine efficacy of 94.1% (95% CI 89.3%,', '96.8%) for the prevention of symptomatic SARS-COV-2 infection with onset at least 14 days', 'after the second injection, with 11 COVID-19 cases in the vaccine group and 185 COVID-19', 'cases in the placebo group 15 The Janssen adenovirus 26 vectored COVID-19 vaccine (Ad26', 'COV2.S) received EUA from the FDA on February 27, 2021 but due to being a viral vector', 'vaccine it will not be further addressed by this study evaluating the simultaneous administration', 'of influenza and mRNA COVID-19 vaccines.', 'BNT162b2 is currently authorized under the FDA EUA for persons 12 - 15 years of age and', 'approved for persons 16 years of age and older while the mRNA-1273 is authorized for persons', \"18 years of age and older. CDC's Advisory Committee on Immunization Practices (ACIP) has\", 'recommended use of these vaccines, according to the specifications in the EUAs; CDC has also', 'published interim clinical considerations for use of COVID-19 vaccines 16,17 Both vaccines are', 'administered intramuscularly with the Pfizer-BioNTech vaccine (30 g, 0.3mL each) being', 'administered 21 days apart and the Moderna vaccine (100 g, 0.5mL each) being administered', '28 days apart. Doses should not be administered earlier than recommended but if given within', 'a 4-day period prior to the scheduled time may be considered valid. Likewise, the second dose', 'should be administered as close as possible to the recommended interval, however if vaccine', 'supplies are limited or if not feasible the vaccine may be administered up to 42 days after the', '11']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'first dose. The vaccines are not considered to be interchangeable, however under extenuating', 'circumstances such as when the brand of the first dose of vaccine is unknown, any mRNA', 'COVID-19 vaccine may be administered 28 days following the first dose16', 'As of August 12, 2021, the FDA amended the Pfizer-BioNTech and Moderna mRNA COVID-19', 'vaccine EUAs to include the use of a third dose of vaccine in specific immunocompromised', 'populations for persons 12 years of age and older and persons 18 years of age or older for the', 'respective vaccines. 18 Additionally, the CDC also recommended that moderate or severely', 'immune compromised populations receive an additional third dose of the mRNA COVID-19', 'vaccines to enhance the immune response19 Subsequent to these actions, the U.S.', 'government plans on the use of the third dose of COVID-19 vaccines as infections rise from the', 'coronavirus Delta variant, citing data indicating diminishing protection from the vaccines over', \"time, pending FDA authorization or approval and a recommendation from CDC's ACIP 20\", 'Local and systemic side effects occurring within the week after vaccination as reported from the', 'BNT162b2 Phase2/3 reactogenicity subset are noted in Table 1. In general, both local and', 'systemic side effects were reported more frequently in those who were younger and following', 'the second dose of vaccine.', 'Table 1. BNT162b2 Reactogenicity (Phase 2/3) 21', 'Dose 1', 'Dose 2', '16-55 years', '>55 years', '16-55 years', '>55 years', 'Local', 'Pain', '83.1%', '71.1%', '77.8%', '66.1%', 'Redness', '4.5%', '4.7%', '5.9%', '7.2%', 'Swelling', '5.8%', '6.5%', '6.3%', '7.5%', 'Systemic', 'Fever', '3.7%', '1.4%', '15.8%', '10.9%', 'Fatigue', '47.4%', '34.1%', '59.4%', '50.5%', 'Headache', '41.9%', '25.2%', '51.7%', '39.0%', 'Chills', '14.0%', '6.3%', '35.1%', '22.7%', 'Vomiting', '1.2%', '0.5%', '1.9%', '0.7%', 'Diarrhea', '11.1%', '8.2%', '10.4%', '8.3%', 'Muscle pain', '21.3%', '13.9%', '37.3%', '28.7%', 'Joint pain', '11.0%', '8.6%', '21.9%', '18.9%', 'Overall, the frequency of any severe systemic event after Dose 1 was <0.9% or less. After Dose', '2, severe systemic events had frequencies of <2% with the exception after Dose 2 of fatigue', '(3.8%) and headache (2.0%). Severe fever (>38.9\u00b0C to 40.0\u00b0C) was reported in the BNT162b2', 'group after Dose 1 for 0.2% and after Dose 2 for 0.8% 14', 'A higher frequency of unsolicited, non-serious adverse events was reported in the vaccine', 'group compared to placebo group and was primarily attributed to local reactions and systemic', 'adverse events in subjects not in the reactogenicity subset and are consistent with solicited', 'reactions/events reported by reactogenicity subset participants during the first 7 days following', 'vaccination. In the all-enrolled population of (total N=43,448), the proportions of participants', '12']\n\n###\n\n", "completion": "END"}